NanoViricides, Inc. (West Haven) announced that it had recently raised more than $4.3 million in equity financing. The company projeced that this additional capital should be sufficient for at least 18 months of operations, or beyond December, 2010, at its current burn rate. In addition, as a result of strong and continued success in its anti-viral drug development programs, management said it believes that the company has significantly improved access to the capital markets for additional funding that may be needed for financing IND studies.